On July 10th, Ge Long Hui reported that Soligenix surged over 633% in mid-trading and closed up 271% at $7.42. According to the news, the company stated that the mid-term data results of long-term treatment evaluation of HyBryte in early excisional T-cell lymphoma patients were positive. Patients responded positively to HyBryte treatment, and all patients seemed to be able to tolerate and safely accept the treatment.
美股异动 | Soligenix一度暴涨超633%，HyBryte作为癌症治疗的扩展治疗数据呈现积极结果
US stock market anomalous | Soligenix soared more than 633%, HyBryte presented positive results as an extension therapy for cancer treatment.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.